Received Feb 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
Innapropiate Schedule for vaccine (2 previous doses 2 years apart); This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 67-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (patient got a first dose of the Shingrix vaccine on 31st October, 2022). On 25-SEP-2024, the patient received the 2nd dose of Shingrix. On 25-SEP-2024, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Innapropiate Schedule for vaccine (2 previous doses 2 years apart)). The outcome of the drug dose administration interval too long was unknown. Additional Information: GSK receipt date: 12-FEB-2025 Other HCP reported that a female patient got a first dose of the Shingrix vaccine on October 31st, 2022 and also did get a second dose on September 25th, 2024. Physician advised to administer a third dose. HCP wanted to know which guidance GSK has on this topic. The patient received 2nd dose of Shingrix,?later than the recommended interval, which led to lengthening of vaccinations schedule (Drug dose administration interval too long).